Introduction
Retinoids are a group of natural and synthetic analogs of vitamin A that have been shown to play an important role in cell differentiation and proliferation (Kastner et al., 1995; Means and Gudas, 1995) . Since retinoid treatment inhibits the growth of a variety of epithelial cancers, such as ovarian carcinomas, retinoids have great promise in the area of cancer chemotherapy and chemoprevention (De Luca, 1991; Gudas et al., 1994; Moon et al., 1994) . However, many tumors have been found to be resistant to the growth inhibitory effects of natural retinoids, such as All-trans retinoic acid (ATRA). Alternatively, synthetic retinoids have been reported to inhibit growth and induce apoptosis in both ATRA-sensitive and ATRA-resistant epithelial carcinoma cell lines (Sun et al., 1997; Wu et al., 1998; Holmes et al., 2000 Holmes et al., , 2002 . The synthetic retinoid 6-[3-(1-admantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid (CD437) has been shown to inhibit growth and induce apoptosis in ovarian carcinoma cell lines Zhang et al., 2000; Appierto et al., 2001; Kumar et al., 2001; Holmes et al., 2002) . Therefore, determination of the cellular mechanism this synthetic retinoid employs to inhibit growth and induce apoptosis of tumor cells could lead to the development of more effective cancer treatments.
CD437 is a conformationally restricted synthetic retinoid that has been studied in a number of cancer models including nonsmall cell lung carcinoma, cervical, breast, and ovarian carcinomas (Shao et al., 1995; Schadendorf et al., 1996; Chao et al., 1997; Hsu et al., 1997; Oridate et al., 1997; Piedrafita and Pfahl, 1997; Spanjaard et al., 1997; Sun et al., 1997; Li et al., 1998; Wu et al., 1998; Holmes et al., 2000 Holmes et al., , 2002 . This retinoid is currently being evaluated in a number of clinical trials and has been reported to induce apoptosis in lung carcinoma cells but not normal noncarcinoma lung cells (Sun et al., 2000b) making this synthetic retinoid a good candidate for study. Our laboratory has demonstrated that CD437 inhibits the growth of and induces apoptosis in ATRA-resistant as well as ATRA-sensitive ovarian carcinoma cells lines (Wu et al., 1998; Holmes et al., 2000 Holmes et al., , 2002 . CD437 has been reported to be an RAR-g-/ RAR-b-selective ligand when used at apoptotic inducing concentrations (10 À6 m) (Spanjaard et al., 1997; Sun et al., 1997; Szondy et al., 1997; Widschwendter et al., 1997; Wu et al., 1998) . Our previous studies demonstrated that the effects of CD437 on ovarian carcinoma cell growth and induction of apoptosis is at least partially RAR-dependent . Previously, using a cell line resistant to CD437-induced apoptosis (CA-CD437R), we demonstrated that the induction of apoptosis in ovarian carcinoma cells was dependent on a cascade of events including TR3 transcription, mitochondrial depolarization, release of cytochrome c and caspase-9, activation of caspase-9, followed by activation of caspase-3 (Holmes et al., 2002) . We also presented preliminary evidence that this cascade of events was dependent on activation of p38 MAP kinase (Holmes et al., 2002) .
In this report, we employed both the CA-OV-3 ovarian carcinoma cell line and the CD437-resistant CA-CD437R cell line to identify early events in the induction of apoptosis by CD437. Through the use of inhibitors of the MAP kinase pathway, we demonstrate that MEK and p38 MAP kinase are necessary for CD437-induced apoptosis. We also determined that the activation of MEK and p38 MAP kinase by CD437 leads to the phosphorylation of MEF2. Phosphorylation of MEF2 induces TR3 expression and TR3 is able to translocate to the cytosol and associate with mitochondria after CD437 treatment. Since each of the early events occurred in the CA-CD437R cell line, the alteration in CA-CD437R cells, which mediates resistance to CD437 lies after TR3 translocation to the mitochondria but prior to mitochondrial depolarization.
Results

Activation of p38 MAP kinase is necessary for CD437-induced growth arrest
To determine the necessity of p38 MAP kinase activity for growth arrest and apoptosis by CD437 treatment, we examined growth and apoptosis of CA-OV-3 cells after combination treatments with CD437 and three separate inhibitors of p38 MAP kinase. Figure 1a shows that when CA-OV-3 cells are treated with CD437 the cell number decreases over time (open circles), indicative of growth arrest and apoptosis. Figure 1a also shows that treatment with three inhibitors of p38 MAP kinase activity (PD169316, SB203580, and SB202190) in conjunction with CD437treatment could block CD437-induced growth arrest.
Inhibitors of the MAP kinase signal cascade block CD437-induced apoptosis
Since we have demonstrated that p38 Map kinase is activated after CD437 treatment of CA-OV-3 cells, we examined members of the MAP kinase signal cascade upstream of p38 MAP kinase activation. In Figure 1b , we used MAP kinase cascade inhibitors in conjunction with CD437 treatment to determine if the inhibition of individual members of the MAP kinase cascade would prevent CD437-induced apoptosis. An apoptosis ELISA was used to measure the extent of apoptosis after 5 days treatment with the CD437 and MAP kinase inhibitors. Figure 1b shows that treatment of CA-OV-3 cells with the commercially available inhibitors of RAS (FTP Inhibitor III) and c-RAF (ZM336372) were not able to block CD437-induced apoptosis; however, the MEK inhibitor (PD98059) was able to block CD437-induced apoptosis to an extent similar to that of the p38 MAP ) were treated with 10 À6 m CD437 and/or p38 MAP kinase inhibitor for 7 days. MAPK kinase inhibitors were added to the culture media 1 h prior to CD437 treatment in the following concentrations; PD169316, 20 mg/ml; SB203580, 10 mg/ ml; SB202190, 10 mg/ml. Cell counting was performed on the indicated days using a hemocytometer. The data represent the mean7the standard deviation of three separate experiments performed in triplicate. CA-OV-3 cells were treated with DMSO (), 10 À6 m CD437 (J), 10 À6 m CD437 with 20 mg/ml PD169316 (.), 10 À6 m CD437 with 10 mg/ml SB203580 (,), and 10 À6 m CD437 with10 mg/ml SB202190 ('). (b) Inhibitors of MAP kinase modulate CD437-induced apoptosis in CA-OV-3 cells. CA-OV-3 ovarian tumor cells (5 Â 10 5 ) were treated with 10 À6 m CD437 alone or with MAP kinase pathway inhibitors FTP inhibitor III (RAS) (100 mg/ml), ZM336372 (c-RAF) (50 mg/ml), PD98059 (MEK) (100 mg/ml), SB203580 (p38) (10 mg/ml), PD169316 (p38) (20 mg/ ml), or SB202190 (p38) (10 mg/ml). The apoptosis ELISA (Material and methods) was performed on day 3. The RAS inhibitor was toxic beyond 3 days. DMSO and the 10 À6 m CD437 alone were used as controls. The data represent the mean7the standard deviation of three separate experiments performed in triplicate CD437 activation of the p38 MAP kinase signal pathway WF Holmes et al kinase inhibitors (SB203580, PD169316, SB202190). Figure 1a and b demonstrates that p38 MAP kinase and MEK activation is necessary for the induction of growth arrest and apoptosis by CD437 treatment of the CA-OV-3 ovarian carcinoma cell line.
p38 MAP kinase is activated by CD437 treatment
Previously we reported that CD437-induced apoptosis of the CA-OV-3 ovarian carcinoma cell line is dependent on p38 MAP kinase activity (Holmes et al., 2002) . Figure 2a and b shows that a 6-h treatment with CD437 increases the activation of p38, as measured with a p38 MAP kinase assay, and the phosphorylation of p38 MAP kinase, as determined by Western blot, in both the CA-OV-3 and CA-CD437R cell lines. No such increase was observed after treatment with ATRA or another synthetic retinoid, 4-HPR. Caspase inhibitor DEVDcmk does not block the phosphorylation indicating that p38 activity and phosphorylation are not dependant on caspase-3 activation. Importantly, it has been reported that activation of p38 MAP kinase, following treatments that induce apoptosis, can lead to the depolarization of the mitochondrial membrane and the activation of caspase-3 (Assefa et al., 2000; Hatai et al., 2000; MacFarlane et al., 2000; Zhuang et al., 2000) .
MEK is phosphorylated by CD437 treatment of the CA-OV-3 cell line
Using an antibody specific for Ser-189 and Ser-207 of phosphorylated MEK, Figure 3 shows that MEK is phosphorylated after 3 h treatment with CD437 in both the CA-OV-3 ( Figure 3a ) and CA-CD437R (Figure 3b ) cell lines. This phosphorylation does not occur following treatment with either ATRA or 4-HPR over the same period of time. The DEVD-cmk caspase-3 inhibitor was used to demonstrate that MEK phosphorylation is not dependent on caspase activity but rather occurs prior to caspase activation. The results of the Western blots shown in Figure 3a and b indicate that MEK activation occurs within 3 h after CD437 treatment. MEK phosphorylation was not detected prior to 3 h of CD437 treatment.
MEK is necessary for CD437-induced p38 MAP kinase activation and apoptosis Figure 4a demonstrates that the MEK inhibitor PD98059 could block the activation of p38 MAP kinase after 6 h of CD437 treatment. The DEVD-cmk caspase-3 inhibitor was used to further demonstrate that the activation of MEK is not the result of caspase activity but occurs prior to caspase activation. These data indicate that MEK activation is required for CD437-induced activation of p38 MAP kinase. Previously we have demonstrated that CD437 treatment activates caspase-3 and that this activity results in apoptosis (Holmes et al., 2002) . Western blotting for PARP demonstrates that the target of CD437-induced caspase activation is not cleaved when the MEK inhibitor PD98059 is added 1 h prior to CD437 treatment ( Figure 4b ). The data in Figure 4a and b indicate that CD437 treatment of CA-OV-3 cells induces MEK activation and that this activation is necessary for CD437-induced apoptosis. Figure 2 p38 MAP kinase is activated and phosphorylated by CD437 treatment. Cell lysates from both the CA-OV-3 cell line and the CA-CD437R cell line were examined by Western blot to detect the active (phosphorylated) form of p38 MAP (p-p38) kinase after 6-h treatment with CD437 (10 À6 m), 4-HPR (10 À5 m) and ATRA (10 À6 m). The membrane was stripped and reprobed for the unphosphorylated form of p38 MAP kinase to account for protein loading. DEVD-cmk treatments were used to detect if the activation of p38 MAP kinase was a result of retinoid-induced caspase-3 activity. The phosphorylation data are compared to p38 activity. MAP kinase (p38) activity was assayed after treatment of ovarian carcinoma cell lines with CD437 (10 À6 m), 4-HPR (10 À5 m) and ATRA (10 À6 m). Ovarian carcinoma cells (4 Â 10 5 cells/well) were cultured in six-well plates. The next day cells were transfected with a luciferase reporter to measure p38 activity and a pCMV-bgal to determine transfection efficiency. At 24 h after transfection, cells were treated with CD437, ATRA, or 4-HPR. After 12 h of treatment, cell lysates were collected and luciferase and b-gal activity was assayed. UVB (60 mJ/cm 
MEF2 is phosphorylated after CD437 treatment
We have previously reported that CD437 treatment of ovarian carcinoma cells leads to the increased transcription of the orphan receptor TR3 in both CA-OV-3 and CA-CD437R cells (Holmes et al., 2002) . TR3 has been reported to be associated with the induction of apoptosis by CD437 through translocation from the nucleus to the cytoplasm resulting in mitochondrial depolarization (Li et al., 2000; Dawson et al., 2001; Holmes et al., 2002; Zhang, 2002) . The depolarization of the mitochondria results in a cascade of events that leads to apoptosis (Li et al., 2000; Dawson et al., 2001; Holmes et al., 2002; Zhang, 2002) . It has been reported that MEF2 is an important transcriptional regulator of TR3 (Youn et al., 1999 Kasler et al., 2000; Liu et al., 2001) and it has been reported that MEF2 can be activated by p38 MAP kinase (Yang et al., 1999; Zhao et al., 1999; Han and Molkentin, 2000; Zhao et al., 2000; Okamoto et al., 2002) . In Figure 5a and b, Western blots show that MEF2 is phosphorylated after CD437 treatment of both CA-OV-3 and CA-CD437R ovarian carcinoma cells and that inhibitors of p38 MAP kinase and MEK could block this phosphorylation. This demonstrates a direct link between CD437-induced activation of MEK and p38 MAP kinase with the activation of MEF2. These results also show that the alteration responsible for the inability of CA-CD437R cells to undergo apoptosis following CD437 treatment occurs downstream of MEF2 phosphorylation.
TR3 targets mitochondria after CD437 treatment
TR3 is an orphan receptor of the steroid/thyroid receptor superfamily that is transcriptionally regulated by MEF2. Previously, we reported that TR3 mRNA increases after CD437 treatment (Holmes et al., 2002) . This finding is supported by reports in other cell models that TR3 mRNA is induced during apoptosis and after CD437 treatment (Liu et al., 1994; Woronicz et al., 1994; Li et al., 1998; Zhang, 2002) . TR3 has been reported to translocate to the cytosol during apoptosis (Katagiri et al., 2000; Li et al., 2000; Liu et al., 2002) . Association of TR3 with mitochondria has been reported to cause the depolarization of the mitochondrial membrane and subsequent release of proapoptotic proteins such as cytochrome c (Li et al., 2000) . Using confocal microscopy, we demonstrate in Figure 6 that TR3 translocates, over time, from the nucleus to the cytosol and associates with mitochondria in both MAP kinase (p38) activity was detected after CD437 (10 À6 m) treatment in the CA-OV-3 ovarian carcinoma cell line. The p38 MAP kinase activity was determined as described in Figure 1 . DMSO and PD169316 (20 mg/ml) with CD437 (10 À6 m)-treated cells were used as a control. DEVD-cmk treatments were used to detect if the activation of p38 MAP kinase was a result of retinoidinduced caspase-3 activity. The data represent the mean7the standard deviation of three separate experiments performed in triplicate. (b) CA-OV-3 cell lysates were examined by Western blot to detect the cleavage of PARP after 3-days treatment with CD437 (10 À6 m) alone or with either p38 MAP kinase inhibitor (PD169316) (20 mg/ml) or MEK inhibitor (PD98059) (100 mg/ml). The membrane was stripped and reprobed for actin account for protein loading. DEVD-cmk treatments were used as a control to ensure that the cleavage of PARP was a result of retinoid-induced caspase-3 activity CD437 activation of the p38 MAP kinase signal pathway WF Holmes et al CD437-sensitive (CA-OV-3) and CD437-resistant (CA-CD437R) ovarian carcinoma cell lines. In cells that are not treated with CD437, the GFP-TR3 protein is sequestered in the nucleus. At 3 h after CD437 treatment, GFP-TR3 is detected in the cytosol and by 6 h after treatment the nucleus is devoid of any GFP-TR3 protein.
In cells expressing GFP-TR3, it appears that all of the GFP-TR3 protein (green) is associated with mitochondria stained by CMXRos (red) resulting in a yellow color by 12 h CD437 treatment. Since we have previously shown that CA-CD437R cells fail to undergo mitochondrial depolarization in response to CD437 treatment, these results allow us to map the defect in CA-CD437R cells to mitochondrial events after TR3 translocation but prior to mitochondrial depolarization. Figure 7 . Only some inhibitors of upstream components of the MAP kinase signal pathway inhibited CD437-induced apoptosis. Interestingly PD98059, an inhibitor of MEK, and SB203580, an inhibitor of p38, blocked the induction of apoptosis by CD437 but the inhibitors of RAS and c-RAF, FTP Inhibitor III, and ZM336372 respectively, did not. These data indicated that the MAP kinase cascade is involved in the induction of apoptosis by CD437.
We have previously presented preliminary evidence for the role of p38 MAP kinase involvement in the induction of apoptosis after CD437 treatment (Holmes et al., 2002) . In this report, we confirm and extend the data supporting the importance of p38 MAP kinase in the CD437 apoptotic pathway.
Phosphorylation and activation of p38 MAP kinase occurs after CD437 treatment but not after treatment with another apoptotic inducing synthetic retinoid, 4-HPR, indicating that there is a divergence in the apoptotic pathway induced by these two retinoids. Studies using the p38 MAP kinase specific inhibitors PD169316, SB203580, and SB202190 confirmed the necessity of p38 for the CD437-induced effects. These data indicate that in the ovarian carcinoma cell line, CA-OV-3, the MAP kinase pathway is necessary for the induction of apoptosis by CD437.
MEK is an upstream activator of p38 that must be phosphorylated to become active. It is important to determine if MEK activation occurs only with the synthetic retinoid CD437 since Sakaue et al. (2001) reported that use of a MEK-specific inhibitor could block the induction of TR3 induced by CD437 treatment despite a lack of measurable activation of the ERK-signaling pathway (Sakaue et al., 2001) . Using an antibody specific for the active form of MEK, we were able to determine that MEK is activated after treatment of CA-OV-3 and CA-CD437R cells with CD437. Further, we were able to determine that the activation of MEK was responsible for the activation of p38 MAP kinase by CD437 treatment through the use of a MEKspecific inhibitor (PD98059). These results further our understanding of the early molecular mechanism responsible for the induction of apoptosis by CD437 in ovarian carcinoma cells and map the activation of p38 directly to the activation of MEK. Moreover, our studies indicate that the CA-CD437R cell line has no form of MEF2 (p-MEF2) after 8-h treatment with CD437 (10 À6 m). The membrane was stripped and reprobed for total MEF2 to account for protein loading. DEVD-cmk treatments were used to detect if the activation of MEF2 was a result of retinoid-induced caspase-3 activity. The phosphorylated form of MEF2 was detected after CD437 treatment but not when either p38 MAP kinase inhibitor (PD169316) (20 mg/ml) or MEK inhibitor (PD98059) (100 mg/ml) was included in the culture medium 1 h before CD437 treatment CD437 activation of the p38 MAP kinase signal pathway WF Holmes et al defect in the activation of the MAP kinase proteins after treatment with CD437. We have determined that the defect in the CA-CD437R cells that causes resistance to the effects of CD437 maps downstream of the MAP kinase signal pathway.
One of the important consequences of activation of the MAP kinase signal pathway is the activation of factors responsible for the transcriptional regulation of response genes. MEF2 is a transcription factor that has been shown to be activated by p38 MAP kinase through phosphorylation (Yang et al., 1999; Zhao et al., 1999 Zhao et al., , 2000 Han and Molkentin, 2000) . MEF2 has been reported to regulate the transcription of the orphan receptor TR3 (nur77) (Youn et al., 1999; Kasler et al., 2000; Liu et al., 2001) . We report that there is a direct link between the activation of MEK and subsequent activation of p38 with the phosphorylation of MEF2. Furthermore, MEF2 is phosphorylated after treatment of both CA-OV-3 and CA-CD437R cells with CD437, indicating Figure 6 CD437 treatments induce TR3 targeting of the mitochondria. Time course of TR3 translocation from the nucleus to the cytosol and the subsequent TR3 association with the mitochondria after 10 À6 m CD437 treatments. Ovarian carcinoma cells, cultured on cover slips in 60 mm plates, were transfected with the pGFP-TR3 construct. The cells were treated with CD437 24 h after transfection. Treatments with CD437 were performed for the indicated times. After CD437 treatment, the cells were stained with the mitochondrial stain CMXRos. The cells were then fixed for 30 min in 4% paraformaldehyde. GFP (GREEN) and CMXRos (RED) were visualized using confocal microscopy, and the two images were overlayed (Overlay). (a) CA-OV-3 cell line. (b) CA-CD437R cell line CD437 activation of the p38 MAP kinase signal pathway WF Holmes et al that no defect exists in the activation of the transcription factor MEF2 in the CA-CD437R cell line. TR3 (nur77) is an orphan receptor of the steroid/ thyroid receptor superfamily. It has been reported that TR3 is induced during apoptosis (Liu et al., 1994; Woronicz et al., 1994) . Furthermore, TR3 is present in the nucleus as a transcription factor but has been shown to translocate to the cytoplasm and cause the depolarization of the mitochondrial membrane (Li et al., 2000; Dawson et al., 2001; Holmes et al., 2002; Zhang, 2002) . This depolarization results in the initiation of apoptosis through the release of cytochrome c and caspase-9. This translocation and association has been reported to be a mechanism for the induction of mitochondrial depolarization and subsequent apoptosis in response to apoptosis-inducing agents, such as CD437 (Li et al., 1998; Zhang, 2002) . In previous work from our laboratory, we determined that TR3 mRNA increased after CD437 treatments in both the CA-OV-3 and CA-CD437R cell lines (Holmes et al., 2002) . In this report, we show that GFP-TR3 is sequestered in the nucleus before treatment with CD437. CD437 treatment induces the translocation, over time, of TR3 to the cytosol and subsequent association with mitochondria in both the CA-OV-3 and CA-CD437R cell lines. These results allow us to map the defect in CA-CD437R cells that allows for resistance to CD437 treatment, to molecular events at the level of mitochondrial membrane depolarization. In the future it would be interesting to determine if p38 MAP kinase inhibitors could block the translocation of TR3. We could not perform this determination at this point of time since the GFP-TR3 construct is constitutive and not dependent on p38-induced transcription.
Previously, we characterized the late stage events of the CD437-induced apoptotic pathway in a cell line resistant to the induction of apoptosis by CD437 (CA-CD437R) (Holmes et al., 2002) . We found that the CA-CD437R cells responded to another apoptosis-inducing agent, 4-HPR, by depolarization of the mitochondria, activation of caspase-9, activation of caspase-3, and subsequent apoptosis but not when treated with CD437. This indicated that the defect that causes CD437 resistance in the CA-CD437R cell line maps upstream of mitochondrial depolarization. Oxygen consumption assays indicated that there might be a defect in the mitochondria of the CA-CD437R cell line since the CA-CD437R cells consumed oxygen at a greatly decreased level in comparison to the parental CA-OV-3 cell line but both the CA-OV-3 and the CA-CD437R cells did respond to CD437 treatment by a decrease in oxygen consumption. In these studies, we did not discover any defects in the early signaling mechanisms of the CA-CD437R cell line, which could result in resistance to CD437-induced apoptosis. Thus the resistance to CD437 by the CA-CD437R cell line maps downstream of TR3 association with mitochondria.
In this report, as well as in our previously published work, we determined that CD437 activated the MAP kinase signal pathway while 4-HPR and ATRA did not. This identifies a divergence in the molecular mechanisms employed by these retinoids to induce growth arrest and apoptosis (Holmes et al., 2002) . We have already determined that c-RAF is not the upstream activator of MEK, but recent reports have shown MEKK1, an upstream activator of MEK, to be necessary for apoptosis induced by cisplatin and TRAIL (tumor necrosis factor (TNF)-related apoptosis inducing ligand); so it is possible that activation of MEK by CD437 may occur through the MEKK1/SEK1 pathway (Gibson et al., 2000; Bild et al., 2002; Sanchez-Perez et al., 2002) . (Holmes et al., 2002) combined with the findings presented here help to define the molecular pathway, depicted in the model, activated by CD437 treatment to induce apoptosis in the CA-OV-3 ovarian carcinoma cell line. CD437 treatment is able to induce the activation of MEK. The activation of MEK is able to induce a cascade of events that include p38 MAP kinase and MEF2 activation resulting in the transcription of TR3. TR3 translocates to the cytoplasm and associates with the mitochondrial membrane inducing its depolarization. Depolarization of the mitochondrial membrane causes the release of caspase-9, cytochrome c, and APAF-1. These three proteins associate and induce activation of caspase-9. Casape-9 activates casape-3 leading to the final stages of apoptosis, such as PARP cleavage. CD437 is able to induce this molecular mechanism in the CA-OV-3 ovarian carcinoma cell line and this mechanism may be a model for future targets of cancer treatment. The early molecular events, described in this report, occur in both the CA-OV-3 and the CA-CD437R cell lines. The CA-CD437R cell line does respond to the apoptosis-inducing agent 4-HPR by depolarization of the mitochondrial membrane, activation of caspase-9, activation of caspase-3, and subsequent apoptosis but this does not occur in response to CD437 treatment. This indicates that, although TR3 associates with the mitochondria, the defect that results in resistance of the CA-CD437R cells maps to CD437-induced mitochondrial membrane depolarization Studies in other cell models designed to determine the molecular events that constitute the apoptotic pathway induced by CD437 have suggested that the mechanism of CD437 action is extremely complex, at times contradictory and in many cases cell-specific. For example, CD437 was shown to induce growth arrest and apoptosis in tumor cell lines via a caspase-dependent pathway in some tumor cells and via caspase-independent pathways in others (Adachi et al., 1998; Zhang et al., 1999) . In addition, treatment with CD437 has been shown to modulate the expression of apoptoticrelated proteins such as bax, bcl-2, DR5, p53, and p21 (WAF1/CIP1) in lung, breast, and small cell carcinoma cells (Shao et al., 1995; Adachi et al., 1998; Li et al., 1998; Sun et al., 1999 Sun et al., , 2000b . Furthermore, CD437 has been reported to act in an RAR-dependent manner in some cells, an RAR-independent mechanism in yet others, and by both RAR-dependent and RARindependent pathways in still other cell models (Hsu et al., 1997; Holmes et al., 2000; Sun et al., 2000a) .
Nevertheless, a number of recent studies in other cell systems have identified molecular events induced by CD437 to be similar to our results. For example Li et al. (1998) reported that expression of nur77 (TR3) plays a critical role in CD437-induced apoptosis of lung cancer cells (Li et al., 1998) . Zhang et al. (1999) showed that CD437 causes a marked increase in the activity of p38, JNK/SAPK serine, and threonine kinases and very rapid induction of apoptosis in HL-60R cells, a retinoicacid-resistant human leukemia cell line (Zhang et al., 1999) . Moreover, apoptosis in this cell model was entirely dependent upon caspase activation since it did not occur in the presence of pan-caspase inhibitors. In contrast, Sakaue et al. (2001) showed that TR3 induction by CD437 was independent of p38 and the induction of TR3 could be blocked by the MEK inhibitor PD98059 in the human lung carcinoma cell line H460 and that MAP kinase inhibitors could not block CD437-induced apoptosis (Sakaue et al., 2001) . TR3 expression and translocation has also been reported to be important for CD437-induced apoptosis in prostate cancer .
CD437 may be a favorable agent for the chemotherapeutic treatment of cancer. Langdon et al. (1998) reported that intraperitoneal and oral administration of CD437 to nude mice with xenographs of a cisplatinresistant ovarian cancer cell line (PE04) significantly inhibited the growth of the cancer cells (Langdon et al., 1998) . It has also been reported that, in the treatment of both normal human lung epithelial cells and human lung cancer cells, CD437 selectively induced apoptosis in human lung cancer cells while sparing normal human lung epithelial cells (Sun et al., 2002) . Furthermore, CD437 was reported to inhibit the growth of a B-cell chronic lymphocytic leukemia cell line (WSU-CLL) in severe combined immunodeficiency (SCID) mice and one of the treated mice survived tumor-free greater than 150 days and was considered cured . While it is clear that CD437 has successfully been used to induce apoptosis in a number of in vitro and in vivo models, concern has been raised about the efficacy of its use in humans because of its toxicity. In response to this concern, a number of less-toxic CD437 analogs have been developed and studied. For example, the CD437 analog MM11453 was reported to inhibit the growth of both retinoid-resistant (HL-60R leukemia, MDA-MB-231 breast, and H292 lung) and retinoid-sensitive (MCF-7 breast, LNCaP prostate, and H460 lung) cancer cell lines by inducing apoptosis. Moreover, prior to inducing apoptosis, MM11453 induced TR3 expression and loss of mitochondrial membrane potential . Likewise, Zhang et al. (2002) has shown that another CD437 analog, 3-CL-AHPC inhibits the growth of human B-CLL and ALL cells both in vitro and in vivo. It is hoped that analogs of CD437 may have therapeutic efficacy for the clinical treatment of a variety of epithelial cancers in the absence of toxicity.
In conclusion, we have demonstrated that CD437 requires the MAP kinase signal pathway and TR3 translocation in order to induce apoptosis in the CA-OV-3 ovarian carcinoma cell line. In addition, the resistance to CD437 by the CA-CD437R cell line maps after TR3 translocation to the mitochondria and before depolarization of the mitochondria. These findings combined with our previous findings (Holmes et al., 2002) provide valuable information to target future cancer treatments to this molecular pathway.
Materials and methods
Cell lines and culture conditions
CA-OV-3 cells were obtained from the American Type Culture Collection (Rockville, MD, USA). Stock cultures of CA-OV-3 and CA-CD437R were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS), 2 mm l-glutamine, 100 U/ml penicillin/streptomycin and 100 U/ml nystatin. The CA-OV-3 cell line was routinely split at a ratio of 1 : 10 weekly. The plates were incubated in an atmosphere of 98% humidified 5% CO 2 . Isolation and characterization of the CA-CD437 cell line, a cell line resistant to apoptosis induced by CD437, is described in previous work (Holmes et al., 2002) .
Retinoids
ATRA was kindly supplied by Hoffmann-La Roche (Nutley, NJ, USA). CD437 was a generous gift of Galderma Research and Development (Sophia Antipolis, France). Fenretinide N-[4-hydroxyphenyl] retinamide (4-HPR) was generously provided by RW Johnson Pharmaceutical Research Institute (Raritan, NJ, USA). Retinoid stock solutions (10 À3 m) prepared in DMSO were stored at À701C. All procedures involving retinoids were carried out under subdued light. In each experiment, control cultures were treated with an equivalent amount of DMSO.
Cell proliferation
Ovarian carcinoma cells were seeded onto 100 mm tissue culture plates at a density of 2 Â 10 4 cells/plate. The cells were incubated for 48 h prior to treatment. The medium, with or without varying concentrations of retinoids and/or inhibitors, was changed every 2 days. On the days indicated, cells were washed with phospho-buffered saline (PBS), trypsinized and counted using a hemocytometer. Cells were assessed for viability using trypan blue. All cell counts were repeated in triplicate.
Apoptosis ELISA
Detection of apoptosis in ovarian cancer cells was performed via an ELISA as described by Salgame et al. (1997) . The ELISA uses a capture monoclonal antibody (LG11-2), which is specific for residues 1-25 of the amino terminal domain of histone H2B, and a biotinylated detection monoclonal antibody (PL2-3), which is specific for the nucleosome subparticle composed of histones H2A, H2B, and DNA. The presence of histones in the cytoplasm is indicative of apoptosis. The ELISA was quantitated by measuring absorbance at 405 nm using a Vmax Kinetic Reader (Molecular Devices, Sunnyvale, CA, USA).
MAP kinase inhibitor studies
Inhibitors for the MAP kinase signal pathway: p38 MAP kinase (PD169316, SB203580, SB202190), RAS (FTP Inhibitor III), c-RAF (ZM336372), and MEK (PD98059) were purchased from Calbiochem (San Diego, CA, USA). Ovarian carcinoma cells were seeded onto 100 mm tissue culture plates at a density of 2 Â 10 4 cells/plate. The cells were incubated for 48 h prior to treatment. MAP kinase inhibitors were added 1 h prior to retinoid treatment. The effect of inhibiting MAP kinase signaling activity on retinoid-induced growth arrest and apoptosis was determined by direct cell counting and/or apoptotic ELISA. All experiments were repeated in triplicate.
Caspase inhibitor studies
Ovarian carcinoma cells were seeded onto 100 mm tissue culture plates at a density of 2 Â 10 4 cells/plate. The cells were incubated for 48 h prior to treatment. At 1 h prior to retinoid treatment, 20 mg/ml of the caspase-3-like inhibitor DEVD-cmk (Bachem, King of Prussia, PA, USA) was added. The effect of inhibiting caspase-3-like activity after retinoid-induced p38 MAP kinase activation and phosphorylation was determined by direct cell counting, apoptotic ELISA, and Western blotting. All experiments were repeated in triplicate.
MAP kinase (p38) In vivo kinase assay
In order to determine p38 MAP kinase activation after treatment with retinoids, a commercially available kit was used to measure MAP kinase activity (MAP kinase In vivo Kinase Assay Kit Clontech, Palo Alto, CA, USA). The cellpermeable p38 MAP kinase inhibitor PD169316 and MEK inhibitor PD98059 (Calbiochem, San Diego, CA, USA) were added to culture media 1 h prior to CD437. Briefly, 4 Â 10 5 cells/well were cultured in six-well plates. These cells were transfected with the p38-target protein ATF, a negative control or a positive control using the Effectene (Quiagen, Valencia, CA, USA) transfection protocol. The cells were cotransfected with a luciferase reporter and pCMV-b-gal (Clontech, Palo Alto, CA, USA). Cells were treated with CD437, 4-HPR, or p38 inhibitor (Calbiochem, San Diego, CA, USA) 24-h after transfection. After 6 h, cell lysates were collected and luciferase activity was measured using a luminometer (Femtomaster FB 12, Zylux Corporation, TN, USA). The results of the luminometer measurements were normalized by b-galactosidase levels.
Antibodies for Western blotting
Proteins associated with CD437-induced apoptosis were determined by Western blotting as we have described previously . Antibodies for these studies; PARP (H-250), p38 MAP kinase (C-20), phospho-MEK-3/6 (B-9), MEK-3/6 (H-90), phospho-MEF2 (Ser 59), MEF2 (H-300) were obtained from Santa Cruz Biotechnologies (Santa Cruz, CA, USA) and phospho-p38 MAP kinase (Thr180/ Tyr182) was obtained from Cell Signaling Technologies (Beverly, MA, USA).
GFP-TR3 transient tranfection and confocal microscopy
The pGFP-TR3 construct was a generous gift from Xioa-kun Zhang (Burnham Institute, La Jolla, CA, USA). CA-OV-3 cells were transfected with the pGFP-TR3 construct using the Effectene (Quiagen, Valencia, CA, USA) transfection protocol. Briefly, 4 Â 10 5 cells/well were cultured in 60 mm plates with cover slips. The cells were treated with CD437 24-h after transfection. Treatments were performed for 0, 3, 6, and 12 h. After CD437 treatment, the medium was replaced with fresh DMEM containing the mitochondrial stain MitoTracker Red CMXRos (8-(4 0 -chloromethyl) phenyl-2, 3, 5, 6, 11, 12, 14, 15-octahydro-1H, 4H, 10H, 13H-diquinolizino-8H-xanthylium chloride) from Molecular Probes (Eugene, OR, USA). CMXRos was added at a final concentration of 0.25 mg/ml for 15 min at room temperature. After two rinses for 2 min each with culture medium the cells were washed with PBS and fixed for 30 min in 4% paraformaldehyde. Fluorescent images were collected and analysed by using an Olympus Fluoview confocal laser scanning microscope (Olympus America Inc., Melville, NY, USA).
